Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M SamsteinChung-Han LeeAlexander N ShoushtariMatthew D HellmannRonglai ShenYelena Y JanjigianDavid A BarronAhmet ZehirEmmet J JordanAntonio OmuroThomas J KaleySviatoslav M KendallRobert J MotzerA Ari HakimiMartin H VossPaul RussoJonathan RosenbergGopakumar V IyerBernard H BochnerDean F BajorinHikmat A Al-AhmadieJamie E ChaftCharles M RudinGregory J RielyShrujal BaxiAlan L HoRichard J WongDavid G PfisterJedd D WolchokChristopher A BarkerPhilip H GutinCameron W BrennanViviane TabarIngo K MellinghoffLisa M DeAngelisCharlotte E AriyanNancy LeeWilliam D TapMrinal M GounderSandra P D'AngeloLeonard SaltzZsofia K StadlerHoward I ScherJose BaselgaPedram RazaviChristopher A KlebanoffRona YaegerNeil H SegalGeoffrey Y KuRonald P DeMatteoMarc LadanyiNaiyer A RizviMichael F BergerNadeem RiazDavid B SolitTimothy A ChanLuc G T MorrisPublished in: Nature genetics (2019)
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) may predict clinical response to ICI. To examine this association more broadly, we analyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non-ICI-treated patients, whose tumors underwent targeted next-generation sequencing (MSK-IMPACT). Among all patients, higher somatic TMB (highest 20% in each histology) was associated with better overall survival. For most cancer histologies, an association between higher TMB and improved survival was observed. The TMB cutpoints associated with improved survival varied markedly between cancer types. These data indicate that TMB is associated with improved survival in patients receiving ICI across a wide variety of cancer types, but that there may not be one universal definition of high TMB.